drugset / Trial / NCT00141154

Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan

NCT00141154

Phase 3 Completed 1234 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To verify the superiority of celecoxib (YM177) 200 mg bid to placebo in treatment of patients with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid.

Timeline

Start
2004-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg
Subject Loxoprofen Small molecule 60 mg

Indications

No indication recorded.